Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Enterprise Value (2019 - 2025)

Bioadaptives' Enterprise Value history spans 7 years, with the latest figure at -$158445.0 for Q4 2025.

  • Quarterly results put Enterprise Value at -$158445.0 for Q4 2025, down 15.26% from a year ago — trailing twelve months through Dec 2025 was -$158445.0 (down 15.26% YoY), and the annual figure for FY2025 was -$158445.0, down 15.26%.
  • Enterprise Value for Q4 2025 was -$158445.0 at Bioadaptives, down from -$59273.0 in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$235.0 in Q2 2024 to a low of -$210582.0 in Q2 2025.
  • The 5-year median for Enterprise Value is -$50235.5 (2022), against an average of -$66054.8.
  • The sharpest move saw Enterprise Value surged 99.41% in 2024, then plummeted 89509.36% in 2025.
  • Year by year, Enterprise Value stood at -$83126.0 in 2021, then skyrocketed by 69.39% to -$25447.0 in 2022, then tumbled by 138.83% to -$60776.0 in 2023, then plummeted by 126.19% to -$137470.0 in 2024, then decreased by 15.26% to -$158445.0 in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$158445.0, -$59273.0, and -$210582.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.